Palisade Bio Jumps as FDA Greenlights Ulcerative Colitis Trial

With regulatory clearance in hand, Palisade Bio is moving its lead candidate into human testing. The company announced Monday that the FDA approved its investigational new drug application for PALI-2108, triggering a 12% surge in share price as investors cheered the path toward treating moderate to severe ulcerative colitis.

Today, 18:50· Money Talk· 679 reads

Palisade Bio Jumps as FDA Greenlights Ulcerative Colitis Trial

The Carlsbad-based biopharmaceutical firm expects to launch the global ASCENTRA-UC study in the latter half of 2026. This trial aims to recruit 204 patients across North America and Europe, comparing two distinct dosage levels against a placebo. Management anticipates primary results from this evaluation by the second half of 2027.

Following the recent market uptick to $2.12 per share, Palisade Bio is already looking beyond its initial target. The company intends to file a separate application in late 2026 to expand the study of PALI-2108 into the treatment of Crohn's disease, signaling a broader strategy to address inflammatory bowel conditions.

Palisade Bio Jumps as FDA Greenlights Ulcerative Colitis Trial

Comments (0)